# Effects of Lactiplantibacillus plantarum GBCC_F0227 on Lipid Accumulation and Lipid Metabolism in High-Fat Diet-Induced Obese Mice

## TL;DR

This study shows that Lactiplantibacillus plantarum GBCC_F0227 reduces lipid accumulation and inflammation in obese mice fed a high-fat diet.

## Contribution

The study demonstrates the novel anti-obesity effects of Lactiplantibacillus plantarum GBCC_F0227 in both cell and mouse models.

## Key findings

- GBCC_F0227 reduced triglyceride accumulation and lipid metabolism gene expression in 3T3-L1 adipocytes.
- In mice, GBCC_F0227 lowered body weight, adipose tissue expansion, and inflammatory markers in white adipose tissue.
- GBCC_F0227 also reduced hepatic lipid accumulation and Pparg and Cd36 gene expression in the liver.

## Abstract

Obesity is characterized by excessive lipid accumulation and chronic inflammation that disrupt metabolic homeostasis. This study investigated the effects of Lactiplantibacillus plantarum GBCC_F0227 on lipid metabolism using differentiated 3T3-L1 adipocytes and a high-fat diet (HFD)-induced obese mouse model. In 3T3-L1 adipocytes, exposure to GBCC_F0227 culture supernatant was associated with reduced intracellular triglyceride accumulation and lower expression of lipid metabolism-related genes. Consistent with the in vitro observations, oral administration of GBCC_F0227 attenuated body weight gain and adipose tissue expansion in HFD-fed mice, together with lower expression of HFD-induced lipid metabolism-related genes (Pparg, Fabp4, Dgat2, and Cs) in white adipose tissue (WAT). GBCC_F0227 treatment also reduced the expression of inflammatory markers (Il-6, Il-1b) as well as Leptin, in epididymal WAT. In the liver, GBCC_F0227 administration lowered the expression of Pparg and Cd36 and reduced hepatic lipid accumulation. Collectively, these findings indicate that GBCC_F0227 administration is associated with coordinated changes in lipid accumulation and lipid metabolism-related gene expression in WAT and liver under HFD conditions. These results highlight the potential of GBCC_F0227 as a probiotic candidate for modulating obesity-associated lipid metabolic alterations.